Sema4 advances precision oncology by
combining best-in-class molecular profiling
with rich longitudinal data to deliver comprehensive, actionable real-world evidence


Sema4 partners with providers, health systems, and payers to support precision care through structuring and analyzing large sets of clinical and genomic data, and using machine learning and natural language processing to draw insights at the individual and cohort level.

As a sponsor of the 2022 American Society of Clinical Oncology (ASCO) conference, Sema4 is proud to partner in the mission to conquer cancer with knowledge. Our continued focus on delivering science-led solutions for personalized patient care can be seen in our latest research and in Sema4 Signal®, our comprehensive data-driven precision oncology portfolio.


Are you looking to collaborate?

Sema4’s advanced predictive modeling and data science expertise uniquely position us to deliver value to and accelerate discovery for collaborators in biopharma, healthcare, and research.

Download our Research Highlight to learn how Sema4 is helping to identify new cancer therapies through integrative network analysis.

Sema4 ASCO Page Research Report Thumbnail

View our 2022 ASCO Abstracts:

  • Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology. View abstract >>
» Poster Session: Monday June 6th, 1:15-4:15 p.m. CDT

  • Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. View abstract >>
» Poster Session: Monday June 6th, 8:00-11:00 a.m. CDT

  • Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP). View abstract >>
» Poster Session: Monday June 6th, 1:15-4:15 p.m. CDT

Poster Session: Monday June 6th, 1:15-4:15 p.m. CDT
View more abstracts online >>

View additional Sema4 studies and research:

  • REPRESENT Study, enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities. Read more >>
  • Research Highlight: Value-Added Clinical Tumor/Normal Whole Exome and Whole Transcriptome Sequencing vs a DNA and RNA Tumor Only Gene Panel for Managing Breast Cancer. Download research >>

Poster Session: Monday June 6th, 1:15-4:15 p.m. CDT
Learn more about Sema4’s latest research by scheduling time to meet with our team via Calendly.


For Oncologists and Health Systems



Detection of hereditary cancer variants, delivered via the Sema4 Traversa™ genomic platform.
Learn more >>


Comprehensive molecular profiling insights to help providers identify therapies and clinical trials.
Learn more >>


Advanced natural language processing (NLP) tools, powered by our Centrellis® health intelligence platform. Learn more >>


For Biopharma

Sema4 Signal® can help research teams to find trial patients and generate data. We work with partners from pre-clinical through clinical trials and commercialization, leveraging Sema4 Signal WES/WTS. This test integrates tumor-normal matched WES with WTS to rapidly deliver the most comprehensive information about somatic and germline alterations across ~18,500 genes, in solid tumors and hematologic malignancies.

Advanced Genetic Profiling Solutions >>


Clinical Development Solutions >>

RWD & Analytics Solutions >>

Rare Disease Solutions >>


Stay Connected or Contact Us Today

Keep up to date with our news updates, exclusive events, and latest research and developments.
Kindly fill out the form below or feel free to call us at 833-486-6260.